Inogen, Inc. (INGN)
| Market Cap | 1.18B |
| Revenue (ttm) | 308.49M |
| Net Income (ttm) | -5.83M |
| Shares Out | 21.98M |
| EPS (ttm) | -0.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 1 |
| Last Price | $53.14 |
| Previous Close | $52.49 |
| Change ($) | 0.65 |
| Change (%) | 1.24% |
| Day's Open | 53.84 |
| Day's Range | 51.50 - 53.77 |
| Day's Volume | 180,456 |
| 52-Week Range | 26.57 - 56.46 |
Inogen's (INGN) fourth-quarter results benefit from higher rental revenues and strength in business-to-business revenues.
Inogen (INGN) delivered earnings and revenue surprises of 17.86% and 6.92%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Inogen (NASDAQ:INGN) fell in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share decreased 483.33% year over year to ($0.23), which beat ...
GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial re...
Inogen (NASDAQ:INGN) announces its next round of earnings this Wednesday, February 24. Here is Benzinga's everything-that-matters guide for this Wednesday's Q4 earnings announcement.
Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that Kriste...
GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Co...
GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will rele...
GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that its Bo...
GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Co...
Inogen (INGN) reported earnings 30 days ago. What's next for the stock?
GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that the Co...
Inogen (INGN) saw revenue decline within its Sales segment in Q3
Inogen Inc. (INGN) CEO Scott Wilkinson on Q3 2020 Results - Earnings Call Transcript
Inogen Inc (INGN) CEO Scott Wilkinson on Q2 2020 Results - Quick Version Earnings Call Transcript
Inogen (INGN) delivered earnings and revenue surprises of -300.00% and -0.82%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today reported financial re...
Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GOLETA, Calif.--(BUSINESS WIRE)--Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced that it will rele...
Inogen (INGN) reported earnings 30 days ago. What's next for the stock?
Investor confidence is high on Inogen (INGN) stock, thanks to solid prospects
Inogen (INGN) saw growth in revenues within its Rental segment in Q2.
Inogen Inc (INGN) CEO Scott Wilkinson on Q2 2020 Results - Earnings Call Transcript
Inogen (INGN) delivered earnings and revenue surprises of 250.00% and -10.08%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Inogen (NASDAQ:INGN) were flat in after-market trading after the company reported Q2 results.
Inogen has been a real boom and bust story in terms of its stock price in recent years.
Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Inogen (INGN) reported earnings 30 days ago. What's next for the stock?
Inogen (INGN) reported growth in business-to-business international and domestic revenues in Q1.
Inogen, Inc. (INGN) CEO Scott Wilkinson on Q1 2020 Results - Earnings Call Transcript
Inogen (INGN) delivered earnings and revenue surprises of 36.36% and 6.69%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investor confidence is high on Inogen (INGN) stock, thanks to solid prospects.
Oxygen therapy has emerged as a necessity for COVID-19 patients.
Inogen (INGN) reported earnings 30 days ago. What's next for the stock?
Inogen (INGN) expects to report a loss per share in the first quarter of 2020.
Inogen (INGN) sees segmental softness in the fourth quarter.
Inogen, Inc. (INGN) CEO Scott Wilkinson on Q4 2019 Results - Earnings Call Transcript
Inogen (INGN) delivered earnings and revenue surprises of -36.36% and 0.02%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Inogen, Inc. (INGN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Big declines in stock price may bring big opportunities for patient investors.
Inogen (INGN) expects direct-to-consumer sales to be its fastest-growing channel in 2020.
Inogen (INGN) reported earnings 30 days ago. What's next for the stock?
Softness in domestic and international business-to-business revenues impact Inogen's (INGN) Q3 results.
Inogen, Inc. (INGN) CEO Scott Wilkinson on Q3 2019 Results - Earnings Call Transcript
Inogen (INGN) delivered earnings and revenue surprises of 34.78% and 0.42%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
About INGN
Inogen, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a single source of supplemental oxygen; Inogen At Home stationary oxygen conce... [Read more...]
| Industry Medical Devices | IPO Date Feb 14, 2014 |
| CEO Scott Wilkinson | Employees 938 |
| Stock Exchange NASDAQ | Ticker Symbol INGN |
Analyst Forecasts
According to 6 analysts, the average rating for Inogen stock is "Hold." The 12-month stock price forecast is 54.33, which is an increase of 2.24% from the latest price.